BCL2 and plasma cell myeloma: Since myeloma cells overexpress anti-apoptotic proteins in a heterogeneous manner, a subset of myeloma cells overexpress B-cell lymphoma-2 (BCL-2) and provide an attractive therapeutic target for BCL-2 inhibitors, such as venetoclax [22].